![]() On the basis of median 18-19 years of follow-up duration, the authors exhibited that progression-free survival of oligodendroglioma could be significantly improved by PCV plus RT. doi: 10.1093/intimm/dxh059.With great interest, we read the study by Lassman et al 1 who reported the combined results of phase III clinical trials of EORTC 26951 and RTOG 9402 launched in 1990s with the aim of investigating the efficacy of radiotherapy (RT) with or without (neo)adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic (grade 3) oligodendroglial tumors. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112) International Immunology. Tahara-Hanaoka S., Shibuya K., Onoda Y., et al. The TIGIT/CD226 axis regulates human T cell function. Lozano E., Dominguez-Villar M., Kuchroo V., Hafler D. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Patients with elevated TIGIT expression have a shorter OS and PFS, and TIGIT expression could be a novel biomarker for prognosis prediction and a valuable therapeutic target for solid tumors. TIGIT expression was associated with OS and PFS in patients with solid tumors. Funnel plots suggested no publication bias for OS ( P = 0.902), and Egger's test supported this conclusion ( P = 0.537). ![]() In addition to cancer type, expression location, sample size, and different statistical analysis methods are also considered the possible causes of heterogeneity between studies. We performed subgroup analysis to explore the source of heterogeneity, colorectal cancer (HR = 2.07, 95% CI, P = 0.518), lung cancer (HR = 1.29, 95% CI, P = 0.094), esophageal cancer (HR = 1.70, 95% CI, P = 0.003), and other cancers (HR = 1.83, 95% CI, P = 0.002). High expression of TIGIT was a risk factor for overall survival (OS) and progression-free survival (PFS) (HR = 1.44, 95% CI, P = 0.01). Increased expression of TIGIT was associated with poor prognosis. Our literature search identified eight papers comprising 1426 patients with solid tumors. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the literature, and Stata 16.0 and Engauge Digitizer 4.1 software were used for data analysis. We performed an online search of PubMed, Embase, Web of Science (WOS), and MEDLINE databases for literature published till March 31, 2021. To fully comprehend the role of TIGIT on the prognosis of patients with solid tumors, we conducted a meta-analysis. The expression levels of TIGIT affect the prognosis of patients with solid tumors. T cell immunoglobulin and ITIM domain (TIGIT) is a recently identified immunosuppressive receptor.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |